BostonGene

Transforming Cancer Care

From Treating a Diagnosis to Treating the Patient

The BostonGene Tumor Portrait™ test is the next-generation of comprehensive genomic testing, providing a personalized approach to cancer treatment.

Value of genomic profiling

Every cancer has a unique genome and understanding the genetic characteristics of your cancer can help fight it at its origin. Comprehensive genomic profiling (CGP) is an essential tool in cancer care that enables doctors to analyze the genetic makeup of a tumor. Using next-generation sequencing (NGS), BostonGene can detect specific genetic changes in the tumor and suggest potential treatment options, including:

1

Tailored biomarker-driven therapy options

Biomarker-driven therapies can lead to improved clinical outcomes and a better quality of life for a wide range of cancer types, such as lung cancer, breast cancer, melanoma and others.

Biomarker-driven therapy matching compared to the standard approach

Higher response

A recent study found that patients who received personalized therapy based on their molecular profile had a higher response rate and longer progression-free survival than those who received unmatched treatment.[1]

Longer progression-free survival

In a study of advanced non-small cell lung cancer, the median progression-free survival is more than twice as long in patients who receive biomarker-driven therapy compared to those who receive standard chemotherapy.[2]

*mPFS – median progression free survival

7.7 months
mPFS* on a **biomarker-driven** therapy

3 months
mPFS* on a **standard** treatment

74% lower risk of progression or death

A study in patients with metastatic melanoma showed that biomarker-driven therapy improved overall survival compared to standard treatment. Based on this report, patients who receive biomarker-driven therapy have a 74% lower risk of cancer progression or death.[3]

2

Clinical trials are matched to your unique genomic profile

According to the American Society of Clinical Oncology (ASCO), clinical trial enrollment is associated with improved cancer survival outcomes.[4]

© 2025 BostonGene Corporation • 100 Beaver Street, Suite 203, Waltham, MA 02453 • phone: +1 781-552-3131 (9:00 AM–5:00 PM ET Monday–Friday)
email: clientservices@bostongene.com • bostongene.com • CLIA ID = 22D2182613 • CAP ID = 8832984 • 05/23/2025

3

Prognostic information

Cancer genetics can also provide important prognostic information. Certain genetic alterations may indicate a higher risk of recurrence or a more aggressive tumor, which can inform treatment decisions and monitoring plans.

4

Screening and prevention strategy for your family members

CGP can evaluate germline alterations, providing information about the likelihood of inherited diseases and cancer. This information can inform screening and prevention strategies for both you and your family and may even guide treatment decisions in certain cases.

About the BostonGene Tumor Portrait™ test

Advanced technology: Using state-of-the-art sequencing technologies, the test extracts critical information from DNA and RNA in approximately 22,000 genes. The results offer a complete picture of the tumor's profile.

Complete analytics: The test analyzes multiple layers of data, including genetic mutations, gene expression levels and immune system activity, to provide a comprehensive understanding of the tumor.

Personalized treatment recommendations: The test provides personalized treatment insights based on the tumor's profile, personal clinical data and the latest scientific evidence.

The BostonGene Tumor Portrait™ test provides the following information to help you and your doctor choose the optimal treatment strategy.



Key biomarkers include actionable gene alterations that may guide your treatment options or help rule out certain therapies.

Potential treatment options based on **the detected biomarkers** and your clinical information summarize the latest treatment recommendations.

Clinical trials are matched based on your test results and medical history. Some clinical trials may use targeted therapies for specific mutations or other tumor characteristics.

© 2025 BostonGene Corporation • 100 Beaver Street, Suite 203, Waltham, MA 02453 • phone: +1 781-552-3131 (9:00 AM–5:00 PM ET Monday–Friday)
email: clientservices@bostongene.com • bostongene.com • CLIA ID = 22D2182613 • CAP ID = 8832984 • 05/23/2025

BostonGene

Recommendations

CGP testing, such as BostonGene's Tumor Portrait™ test, is recommended in various cancer clinical guidelines as a useful tool for identifying biomarkers that can guide treatment selection:

ASCO — ASCO guidelines – for patients with advanced solid tumors who have exhausted standard treatment options.

NCCN — NCCN guidelines – for patients with advanced or metastatic cancer.

Financial support

At BostonGene, we understand that the cost of medical care can be a burden for patients and we want to ensure that financial constraints do not prevent you from receiving the necessary tests to guide treatment selection. We offer a financial assistance program to help patients decrease their out-of-pocket expenses.

If you are in need of financial assistance, please complete the form to apply for BostonGene's financial assistance program. We will take into account your household income and other life circumstances when considering your financial application.

Financial assistance

Test ordering

To order the BostonGene Tumor Portrait™ test, you should speak with your doctor.

Your physician will complete the required paperwork and order the test.

BostonGene provides an easy-to-use kit for collecting tumor and normal specimens for analysis.

- A tumor sample is collected via tissue from a recent biopsy or surgery, which BostonGene will obtain on your behalf.
- A normal sample is collected via saliva, blood or buccal swab obtained in your oncologist's clinic or through a collection kit sent to your home.

Once the report is ready, the results will be securely shared with your physician.

NCCN Guidelines for Patients | National Cancer Institute (NCI) | American Cancer Society (ACS) | American Society of Clinical Oncology (ASCO) | American Association for Cancer Research | American Cancer Society Cancer Action Network℠ | MD Anderson Cancer Center | Memorial Sloan Kettering Cancer Center | Dana Farber Cancer Institute

© 2025 BostonGene Corporation • 100 Beaver Street, Suite 203, Waltham, MA 02453 • phone: +1 781-552-3131 (9:00 AM–5:00 PM ET Monday–Friday)
email: clientservices@bostongene.com • bostongene.com • CLIA ID = 22D2182613 • CAP ID = 8832984 • 05/23/2025

BostonGene

References:

1. Tsimberidou, A. M., Hong, D. S., Ye, Y., Cartwright, C., Wheler, J. J., Falchook, G. S., ... & Kurzrock, R. (2017). Initiative for molecular profiling and advanced cancer therapy (IMPACT): an MD Anderson precision medicine study. JCO precision oncology, 1, 1-18.
2. Shaw, A. T. (2013). Kim dW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med, 368, 2385-2394.
3. Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., ... & McArthur, G. A. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New England Journal of Medicine, 364(26), 2507-2516.
4. Unger, J. M., Cook, E., Tai, E., & Bleyer, A. (2016). The role of clinical trial participation in cancer research: barriers, evidence, and strategies. American Society of Clinical Oncology Educational Book, 36, 185-198.

Information for patients

To learn more about the BostonGene Tumor Portrait™ test visit www.bostongene.com